Can Amarin's Stock Recover From Its 70% Implosion?

When news broke on March 30 that a district judge in Nevada invalidated patents that protected its Vascepa drug on the grounds of "obviousness", its share price fell off a steep cliff. Vascepa is a fish-oil derivative pill that helps patients with high triglyceride levels and can reduce their risk of heart attack and stroke. The drug is a significant piece of the company's business, and Amarin is appealing the judge's decision. The big question is whether the stock can recover from this and if it's too risky to buy today. Let's take a closer look to find out.